Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Long-term outcomes of combining prostate brachytherapy and metastasis-directed radiotherapy in newly diagnosed oligometastatic prostate cancer: A retrospective cohort study.

Tsumura H, Ishiyama H, Tabata KI, Sekiguchi A, Kawakami S, Satoh T, Kitano M, Iwamura M.

Prostate. 2019 Apr;79(5):506-514. doi: 10.1002/pros.23757. Epub 2018 Dec 26.

PMID:
30585345
2.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502
3.

Prostate-specific antigen nadir after high-dose-rate brachytherapy predicts long-term survival outcomes in high-risk prostate cancer.

Tsumura H, Satoh T, Ishiyama H, Tabata K, Komori S, Sekiguchi A, Ikeda M, Kurosaka S, Fujita T, Kitano M, Hayakawa K, Iwamura M.

J Contemp Brachytherapy. 2016 Apr;8(2):95-103. doi: 10.5114/jcb.2016.59686. Epub 2016 Apr 29.

4.

Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.

Fitch DL, McGrath S, Martinez AA, Vicini FA, Kestin LL.

Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1430-9. Epub 2006 Jun 12.

PMID:
16765527
5.

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.

Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Mottet N.

Eur Urol. 2017 Apr;71(4):630-642. doi: 10.1016/j.eururo.2016.08.002. Epub 2016 Aug 31.

PMID:
27591931
6.

A systematic review of contemporary management of oligometastatic prostate cancer: fighting a challenge or tilting at windmills?

Slaoui A, Albisinni S, Aoun F, Assenmacher G, Al Hajj Obeid W, Diamand R, Regragui S, Touzani A, Bakar A, Mesfioui A, Karmouni T, Ameur A, Elkhader K, Koutani A, Ibnattya A, Roumeguere T, Peltier A.

World J Urol. 2019 Jan 31. doi: 10.1007/s00345-019-02652-7. [Epub ahead of print]

PMID:
30706122
7.

Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen Z, Lief JH, Adamovich E.

Urology. 2005 Jan;65(1):95-100.

PMID:
15667872
8.

Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.

Demanes DJ, Brandt D, Schour L, Hill DR.

Am J Clin Oncol. 2009 Aug;32(4):342-7. doi: 10.1097/COC.0b013e31818cd277.

PMID:
19398902
9.

Clinical outcomes of high-dose-rate brachytherapy and external beam radiotherapy in the management of clinically localized prostate cancer.

Kotecha R, Yamada Y, Pei X, Kollmeier MA, Cox B, Cohen GN, Zaider M, Zelefsky MJ.

Brachytherapy. 2013 Jan-Feb;12(1):44-9. doi: 10.1016/j.brachy.2012.05.003. Epub 2012 Jul 24.

10.

Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.

Denham JW, Joseph D, Lamb DS, Spry NA, Duchesne G, Matthews J, Atkinson C, Tai KH, Christie D, Kenny L, Turner S, Gogna NK, Diamond T, Delahunt B, Oldmeadow C, Attia J, Steigler A.

Lancet Oncol. 2014 Sep;15(10):1076-89. doi: 10.1016/S1470-2045(14)70328-6. Epub 2014 Aug 14.

PMID:
25130995
11.

Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy.

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Lief JH, Allen Z, Adamovich E.

Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):32-43.

PMID:
15629591
12.

Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.

Kijima T, Fujii Y, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Saito K, Koga F, Masuda H, Kawakami S, Kihara K.

BJU Int. 2012 Oct;110(8):1149-55. doi: 10.1111/j.1464-410X.2012.10959.x. Epub 2012 Feb 28.

13.

[Predictive factor analysis of time to progression of castration-resistant prostate cancer after androgen deprivation therapy].

Ji GJ, Huang C, Song G, Li XS, Song Y, Zhou LQ.

Beijing Da Xue Xue Bao Yi Xue Ban. 2017 Aug 18;49(4):657-662. Chinese.

14.

High dose rate (HDR) brachytherapy with conformal radiation therapy for localized prostate cancer.

Deger S, Boehmer D, Roigas J, Schink T, Wernecke KD, Wiegel T, Hinkelbein W, Budach V, Loening SA.

Eur Urol. 2005 Apr;47(4):441-8. Epub 2005 Jan 18.

PMID:
15774239
15.

Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).

James ND, Spears MR, Clarke NW, Dearnaley DP, De Bono JS, Gale J, Hetherington J, Hoskin PJ, Jones RJ, Laing R, Lester JF, McLaren D, Parker CC, Parmar MKB, Ritchie AWS, Russell JM, Strebel RT, Thalmann GN, Mason MD, Sydes MR.

Eur Urol. 2015 Jun;67(6):1028-1038. doi: 10.1016/j.eururo.2014.09.032. Epub 2014 Oct 6.

16.

High-dose-rate brachytherapy monotherapy without androgen deprivation therapy for intermediate-risk prostate cancer.

Patel S, Demanes DJ, Ragab O, Zhang M, Veruttipong D, Nguyen K, Park SJ, Marks L, Pantuck A, Steinberg M, Kamrava M.

Brachytherapy. 2017 Mar - Apr;16(2):299-305. doi: 10.1016/j.brachy.2016.11.002. Epub 2016 Dec 10.

PMID:
27965117
17.

May non-metastatic clinically localized castration-resistant prostate cancer after primary androgen ablation benefit from salvage prostate radiotherapy?

Botticella A, Guarneri A, Filippi AR, Levra NG, Munoz F, Ragona R, Gontero P, Ricardi U.

J Cancer Res Clin Oncol. 2013 Nov;139(11):1955-60. doi: 10.1007/s00432-013-1520-3. Epub 2013 Sep 22.

PMID:
24057645
19.
20.

The impact of primary Gleason grade on biochemical outcome following brachytherapy for hormone-naive Gleason score 7 prostate cancer.

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen ZA, Adamovich E.

Cancer J. 2005 May-Jun;11(3):234-40.

PMID:
16053667

Supplemental Content

Support Center